| Line Item | 2025-11-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $149K | — | +8.5% |
| SG&A Expense | $464K | — | +1.4% |
| Operating Income | -$613K | — | -3.0% |
| Net Income | -$571K | — | -3.4% |
| EPS (Basic) | -$0.01 | — | +0.0% |
| EPS (Diluted) | -$0.01 | — | +0.0% |
| Line Item | 2025-11-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $5.9M | -10.0% | +717.0% |
| Current Assets | $6.1M | -8.3% | +33.6% |
| Total Assets | $6.1M | -7.8% | +34.8% |
| Current Liabilities | $245K | +25.9% | -32.1% |
| Total Liabilities | $245K | +25.9% | -32.1% |
| Stockholders' Equity | $5.9M |
| Line Item | 2025-11-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$628K | — | -19.0% |
| Investing Cash Flow | -$30K | — | — |
| +40.5% |